NCT00960830

Brief Summary

The purpose of this study is to evaluate if the use of antidepressant medication in depressed patients with implantable cardioverter defibrillator reduces the number of ICD's shocks as it improves depressive affect.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for not_applicable depression

Timeline
Completed

Started Apr 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2008

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2008

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

July 21, 2009

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 18, 2009

Completed
Last Updated

August 18, 2009

Status Verified

August 1, 2009

Enrollment Period

1 year

First QC Date

July 21, 2009

Last Update Submit

August 17, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of implantable cardioverter defibrillator shocks

    one year

Secondary Outcomes (1)

  • improvement of depression

    one year

Study Arms (2)

mirtazapine

PLACEBO COMPARATOR
Drug: mirtazapine

mirtazapine, sugar pill

PLACEBO COMPARATOR
Drug: mirtazapine

Interventions

mirtazapine 15 mg daily tablets

Also known as: mirtazapine 1500 mtz
mirtazapine

Eligibility Criteria

Age65 Years - 87 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • cardioverter implanted patients
  • depression
  • anxiety

You may not qualify if:

  • heart failure
  • other diseases reducing physical fitness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cl Sn Nicol

San Nicolás, Bs As, 1900, Argentina

Location

MeSH Terms

Conditions

DepressionAnxiety Disorders

Interventions

Mirtazapine

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Intervention Hierarchy (Ancestors)

DibenzazepinesHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • daniel jl serrani, MD

    facultad de psicologia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 21, 2009

First Posted

August 18, 2009

Study Start

April 1, 2007

Primary Completion

April 1, 2008

Study Completion

November 1, 2008

Last Updated

August 18, 2009

Record last verified: 2009-08

Locations